



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Clopidogrel/Acetylsalicylic acid Viatris

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification ¹ issued on	Commission Decision Issued ² / amended on	Product Information affected ³	Summary
IG/1688	A.2.a - Administrative change - Change in the (invented) name of the medicinal product for CAPs	15/01/2024		SmPC, Labelling and PL	
IB/0009/G	This was an application for a group of variations.	08/09/2023	22/09/2023	SmPC and PL	

¹ Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

² A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

³ SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).



	<p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH</p> <p>C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH</p>				
IB/0007	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	02/08/2022	28/07/2023	SmPC and PL	
IB/0008	B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data	28/07/2022	n/a		

IAIN/0006/G	<p>This was an application for a group of variations.</p> <p>B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer</p> <p>B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer</p>	15/11/2021	n/a		
T/0005	Transfer of Marketing Authorisation	12/08/2021	19/10/2021	SmPC, Labelling and PL	
IB/0004	C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH	11/01/2021	25/02/2021	SmPC and PL	
IA/0003	B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure	31/07/2020	n/a		
IB/0001	B.II.f.1.z - Stability of FP - Change in the shelf-life or storage conditions of the finished product - Other variation	03/03/2020	25/02/2021	SmPC	
IAIN/0002	C.I.3.a - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure	28/02/2020	25/02/2021	SmPC and PL	

	concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Implementation of wording agreed by the competent authority				
--	---	--	--	--	--